These evaluations may lead to primary or secondary diagnoses of mild cognitive impairment such as Alzheimer’s or Parkinson’s Disease, the latter of which would benefit from dopamine agonists and cholinesterase inhibitors [44]. This evidence concerns the gene BCHE and Parkinson disease.